e.g. mhealth
Search Results (1 to 7 of 7 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 JMIRx Med
- 1 JMIR Cancer
- 1 JMIR Formative Research
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Women who test positive for a BRCA genetic mutation are at a higher risk of developing hereditary breast and ovarian cancer, which impacts their health, reproductive choices, and identity [10,11]. Within their lifetime, individuals with a BRCA mutation have up to a 75% increased risk in developing breast or ovarian cancer [12].
J Med Internet Res 2025;27:e67794
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
In NPC and the other known EBV-associated cancers, EBV inhibits the FA-BRCA pathway by various methods, including using viral micro RNAs to downregulate BRCA1 [14], hijacking other pathway components [15,16], and destabilizing SMC5/6-mediated chromatin interactions [17,18]. In GC, EBV infection and FA-BRCA pathway status are mutually exclusive [19], implying that EBV infection is approximately equivalent to disabling the FA-BRCA pathway. In DLBCL, the best prognostic marker is FA-BRCA pathway status [20].
JMIRx Med 2025;6:e50712
Download Citation: END BibTex RIS
Paradigmatic Approach to Support Personalized Counseling With Digital Health (iKNOW)
To provide additional patient-relevant information (eg, related to psychosocial support or possible lifestyle changes), information materials of the German Cancer Information Centre [21], the German Cancer Aid [22], and the BRCA network [23] were summarized and the information was referenced in the i KNOW database. Additionally, several workshops and focus group interviews with expert patients from the BRCA network were held to optimally include the patients’ perspectives in the development of the tool.
JMIR Form Res 2023;7:e41179
Download Citation: END BibTex RIS
For men with metastatic, castration-resistant PCa who carry BRCA mutations, the FDA has approved 2 poly-ADP ribose polymerase (PARP) inhibitors as targeted therapy after progression on standard therapy [8-10]. BRCA mutation status is also included in guidelines for PCa screening [4], and men with BRCA2 mutations have more reclassification during active surveillance for favorable-risk disease [11].
JMIR Cancer 2021;7(3):e27063
Download Citation: END BibTex RIS